CFD
IBRX icon

Creative Financial Designs’s ImmunityBio IBRX Stock Holding History

Creative Financial Designs’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-120
Closed -$2K – 1333
2020
Q4 		$2K Hold
120
– – ﹤0.01% 1133
2020
Q3 		$1K Hold
120
– – ﹤0.01% 1155
2020
Q2 		$1K Buy
+120
New +$678 ﹤0.01% 1098

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Creative Financial Designs's IBRX Position: Q1 2021 in Review

Creative Financial Designs sold out of ImmunityBio (IBRX) in Q1 2021, closing a stake of 120 shares — an estimated $2K sold.

Creative Financial Designs first reported a position in IBRX in Q2 2020 and held it in 3 quarters. The position peaked at $2K in Q4 2020. 126 funds tracked by Wall St. Rank hold IBRX as of Q1 2021.

  • Creative Financial Designs reported no remaining ImmunityBio position as of Q1 2021 after selling out during the quarter.
  • Creative Financial Designs sold 120 ImmunityBio shares in Q1 2021, an estimated $2K.
  • Creative Financial Designs first reported a position in ImmunityBio in Q2 2020 and held it in 3 quarters.
  • Creative Financial Designs's ImmunityBio position peaked at $2K in Q4 2020.
  • 126 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2021.

Based on Creative Financial Designs's 13F filing for Q1 2021, filed 19 Apr 2021.